Abstracts tagged "prevention"

Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0113 • ACR Convergence 2020
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
Marielys Figueroa Sierra¹, Atefeh Vafa¹, Shu Cao², Yuanyuan Lu³, Helen Bateman⁴, John Carter¹, Yih Chang Lin², Raquel Cuchacovich¹, Marcos Maldonado⁴, Joanne Valeriano-Marcet¹ and Gabriela Montes-Rivera⁴, ¹University of South Florida, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, FL, ³Biostatistician at Graduate Medical Education Department, Tampa, FL, ⁴James A. Haley VA, Tampa, FL
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy. It is imperative to identify these patients…
Abstract Number: 0310 • ACR Convergence 2020
The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁵, Christopher Ritchlin⁶, Cheryl Rosen⁷, Richard Cook² and Dafna Gladman³, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, Canada, ⁶Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Nancy Desai¹, Hanni Menn-Josephy ¹, Ramon Bonegio ¹, Christina Lam ¹, Anna Kancharla ¹ and Michael York ¹, ¹Boston Medical Center, Boston
Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…
Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting
Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Ohoud AlAhmed¹, Amanda Way ², Shoghik akoghlanian ², Fatima Barbar-Smiley ², Stephanie Lemle ², Darby MacDonald ², Kelly Wise ², Stacy Ardoin ² and Vidya Sivaraman ³, ¹Nationwide Children's Hospital, Columbu, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…
Abstract Number: 2105 • 2019 ACR/ARP Annual Meeting
The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Kengo Akashi¹, Sadao Jinno ², Akira Onishi ¹, Mai Yamashita ³, Yoko Nose ⁴, Takaichi Okano ¹, Yo Ueda ¹, Sho Sendo ¹, Jun Saegusa ¹ and Akio Morinobu ¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ³Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan, ⁴Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
Background/Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as a first-line agent of pneumocystis pneumonia (PCP) prophylaxis for those who receive prolonged high-dose glucocorticoids. Alternative agents can be…
Abstract Number: 2268 • 2019 ACR/ARP Annual Meeting
Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation
Chelsie Fleischer¹, Marie Feser ², Elizabeth Bemis ³, Christopher Striebich ⁴, LauraKay Moss ⁴, Vasilisa Kormendi ⁵, Sharon White ⁵, V. Michael Holers ⁶, Mark Harrison ⁷ and Kevin Deane ², ¹University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁵University of Colorado Denver, School of Medicine, Aurora, CO USA, Aurora, CO, ⁶University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁷The University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, Vancouver, BC, Canada
Background/Purpose: In rheumatoid arthritis (RA) development, autoantibodies to citrullinated protein antigens (ACPA) are elevated in the blood before clinically-apparent synovitis develops. These findings underpin the…
Abstract Number: 295 • 2018 ACR/ARHP Annual Meeting
Implementing a Staff Tobacco Cessation Protocol Increases Quit Line Referrals in a Community Rheumatology Practice
Ann M. Chodara¹, Edmond Ramly^2,3, Douglas White⁴, Heather Johnson⁵, Andrea Gilmore-Bykovskyi⁶ and Christie M. Bartels⁷, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ³Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Gundersen Lutheran - Onalaska Clinic, Onalaska, WI, ⁵Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Wisconsin School of Nursing, Madison, WI, ⁷Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Smoking remains the leading preventable cause of US mortality and predicts higher incidence, greater severity, and reduced treatment response in many rheumatologic conditions. Despite…
Abstract Number: 344 • 2018 ACR/ARHP Annual Meeting
Use of Lean Six-Sigma Methodologies to Improve Pneumococcal Vaccination Rates Among Immunocompromised Veterans with Rheumatologic Diseases: A Quality Improvement Project
Melissa Swee¹, Jaime Wilson² and Bharat Kumar³, ¹Transplant Nephrology, University of Iowa, Iowa City, IA, ²Iowa City Veterans Affairs Medical Center, Iowa City, IA, ³Internal Medicine-Division of Immunology, University of Iowa, Iowa City, IA
Background/Purpose: Pneumonia is a leading cause of morbidity and mortality in the United States among immunocompromised individuals with rheumatologic diseases. Despite the publication of Advisory…
Abstract Number: 1235 • 2018 ACR/ARHP Annual Meeting
Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids
Jun Won Park¹, Jeffrey R. Curtis², Hajeong Lee³, Yeong Wook Song⁴ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁴Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Although use of glucocorticoid increases the risk of tuberculosis (TB) disease, there has been few studies investigating its incidence and risk/benefit assessment of the…
Abstract Number: 1596 • 2018 ACR/ARHP Annual Meeting
Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting
Linh Truong¹, Nicole Ridolfi¹ and Maida Wong^2,3, ¹Internal Medicine, University of California, Irvine, Orange, CA, ²Department of Medicine, University of California, Irvine, orange, CA, ³Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA
Background/Purpose: There is accumulating evidence that shows an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors among the psoriatic arthritis (PsA) population. The aim…
Abstract Number: 1642 • 2018 ACR/ARHP Annual Meeting
Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial
Anna Molto¹, Adrien Etcheto², Serge Poiraudeau³, Laure Gossec⁴, Pascal Claudepierre⁵, Martin Soubrier⁶, Françoise Fayet⁷, Daniel Wendling⁸, Philippe Gaudin⁹, Emmanuelle Dernis¹⁰, Sandrine Guis¹¹, Sophie Pouplin¹², Adeline Ruyssen-Witrand¹³ and Maxime Dougados¹⁴, ¹Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ²Department of Rheumatology, Paris Descartes University, Hôpital Cochin, Paris, France, ³Univ. Paris Descartes, PRES Sorbonne Paris, INSERM UMR-S 1153 et Institut fédératif de recherche sur le handicap, Paris, France, Paris, France, ⁴Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France, ⁵Hôpital Henri Mondor, Créteil, France, ⁶Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷CHU Gabriel Montpied, Clermont Ferrand, France, ⁸Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ⁹Grenoble University Hospital, France, Grenoble, France, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹Rheumatology Department, CHU, Marseile, France, ¹²Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ¹³Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹⁴Paris Descartes University, Hôpital Cochin, Paris, France
Background/Purpose: Specific recommendations for the detection/prevention of comorbidities have been proposed for patients with SpA. However, we know that often a gap exists between recommendation…
Abstract Number: 1909 • 2018 ACR/ARHP Annual Meeting
Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women
Xinyi Liu¹, Cianna Leatherwood¹, Sara K. Tedeschi¹, Medha Barbhaiya², Cameron Speyer¹, Bing Lu³, Karen Costenbader¹, Elizabeth Karlson¹ and Jeffrey A. Sparks¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay…
Abstract Number: 2250 • 2017 ACR/ARHP Annual Meeting
Linguistic Differences in Gout-Related Online Content: A Comparison of Professional Health Literature for Consumers Vs Patients’ Online Discussions of Gout
W. Benjamin Nowell¹, Kayla Jordan², Kelly Gavigan¹, Louis Tharp¹, Jeffrey R. Curtis³ and James Pennebaker⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²University of Texas at Austin, Austin, TX, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Psychology, University of Texas at Austin, Austin, TX
Background/Purpose: Non-adherence to gout medication is high. This may be due in part to patients’ belief that gout is primarily caused by overindulgence in certain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].